Abstract 3715
Background
The main objective of this project is to develop a mobile application (APP) for monitoring and controlling the management of the therapeutic regime in this group of people, with a view to strengthening communication among patients and health professionals, favoring adherence to therapeutic indications and responding, in a timely manner and in a proactive manner, to the symptoms or complications that may arise associated with the disease, thereby improving the efficacy of the therapy, preventing complications and improving its perception of health and quality of life. In fact, health interventions must transform behavior towards the desired improvement and empowerment of the person, thus facilitating self-management. Its final presentation will be on the form of an APP, which will improve the well-being and quality of life of people with cancer, bringing gains in efficiency and health outcomes, broadening the sense of the adequacy of policies of health. The expected results with the implementation of this APP are: improve and monitor patient adherence to oral and supportive therapies; to prevent, the appearance of complications or symptoms associated with the treatment, through preventive indications of self-care (green alert level); improve patients responses, through self-care uncontrolled complications (yellow alert level); signaling to the patient and health services, uncontrolled symptoms with high severity (red alert level); improve the efficiency of health teams with regard to self-management of the disease and produce and disseminate knowledge in oncology. At this time the project is already at an advanced stage of development. Systematic reviews of the literature were developed to support the interventions included in the APP. The interventions were categorized by the two levels of self-care and were submitted to expert evaluation using the Delphi technique.
Trial design
Systematic reviews of the literature were developed to support the interventions included in the APP. The interventions were categorized by the two levels of self-care and were submitted to expert evaluation using the Delphi technique. The project has already been tested on an initial sample of 40 patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract